Aduro BioTech   Report issue

For profit Phase 1 Phase 2
Founded: Berkeley CA United States (2000)

Organization Overview

First Clinical Trial
2011
NCT01417000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Aduro Biotech, Inc. | Hanlee P. Ji, MD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Astrocytoma (Phase 1)

Brain Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 1)

Glomerulonephritis, IGA (Phase 1)

Head and Neck Neoplasms (Phase 2)

Kidney Diseases (Phase 1)

Lymphoma (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 28